Antibodies to sulfated glycolipids in Guillain-Barré syndrome

J Neurol Sci. 1991 Sep;105(1):108-17. doi: 10.1016/0022-510x(91)90126-r.


Sera from 53 patients with acute Guillain-Barré syndrome (GBS), 15 patients with chronic inflammatory demyelinating polyneuropathy (CIDP), 13 patients with other neurological diseases (OND) and 31 healthy controls were tested for IgM and IgG antibodies to sulfoglucuronyl paragloboside (SGPG) and sulfatide by both an ELISA and a thin-layer chromatogram-overlay technique. Although the mean levels of anti-SGPG or anti-sulfatide antibodies in GBS patients were not elevated compared to controls, the occurrence of anti-SGPG antibodies was more frequent in GBS patients than in controls (P less than 0.02). Acute GBS patients with antibodies to SGPG or sulfatide were clinically indistinguishable from other GBS patients. Our data suggest that elevated levels of antibodies to SGPG could be important in the pathogenesis of neuropathy in some GBS patients.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Autoantibodies / analysis*
  • Carbohydrate Sequence
  • Cats
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Gangliosides / immunology
  • Glycolipids / immunology*
  • Glycolipids / isolation & purification
  • Humans
  • Immunoglobulin G / analysis*
  • Immunoglobulin M / analysis*
  • Male
  • Middle Aged
  • Molecular Sequence Data
  • Nervous System Diseases / immunology
  • Polyneuropathies / immunology
  • Polyradiculoneuropathy / immunology*
  • Polyradiculoneuropathy / physiopathology
  • Sulfoglycosphingolipids / immunology


  • Autoantibodies
  • Gangliosides
  • Glycolipids
  • Immunoglobulin G
  • Immunoglobulin M
  • Sulfoglycosphingolipids
  • sulfoglycolipids